Interpace Biosciences®, Inc. Annual report pursuant to Section 13 and 15(d)

Stock-Based Compensation (Details Narrative)

Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based compensation arrangements, options, grants in period, weighted average exercise price	$ 1.04	$ 1.49
Share-based compensation aggregate fair value of option	$ 1,200	$ 1,100
Weighted-average grant date fair value of options vested	$ 1.61
Aggregate fair value of restricted stock units	$ 100	$ 100
Total unrecognized compensation cost related to unvested stock options and restricted stock units	$ 1,100
Stock Incentive Plan [Member]
Share-based compensation arrangement by share-based payment award, description	Stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, expire 10 years from the date they are granted, and generally vested over a one to three-year period for members of the Board of Directors and a one to three-year period for employees. Upon exercise, new shares can be issued by the Company. The Company granted stock options in 2018 which vest one-third each year on the anniversary of the grant date. The Company granted stock options in 2017 which vested monthly over a one-year period. SARs are generally granted with a grant price equal to the market value of the common stock on the date of grant, vest one-third each year on the anniversary of the date of grant and expire five years from the date of grant. The restricted shares and restricted stock units granted to employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. Restricted shares and restricted stock units granted to board members generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances.